KDOQI (Kidney Disease Outcomes Quality Initiative)


Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | History of KDOQI

  KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

Acronyms and Abbreviations

AASK African American Study of Kidney Disease and Hypertension

ABCD Appropriate Blood Pressure Control in Diabetes

ABPM ambulatory blood pressure monitoring

ACE angiotensin-converting enzyme

ACE-I angiotensin-converting enzyme inhibitor

ADA American Diabetes Association

AGEs advanced glycation end-products

AHA American Heart Association

AHRQ Agency for Healthcare Research and Quality

AIPRD ACE Inhibition in Progressive Renal Disease

AIPRI ACE Inhibition in Progressive Renal Insufficiency

AJKD American Journal of Kidney Diseases

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

ANBP2 Second Australian National Blood Pressure Study

ARB angiotensin-receptor blocker

ARIC Atherosclerosis Risk in Communities

ASCVD atherosclerotic cardiovascular disease

BMI body mass index

BSA body surface area

BUN blood urea nitrogen

CABG coronary artery bypass graft

CAPP Captopril Prevention Project

CARI Caring for Australians with Renal Impairment

CBP casual blood pressure

CCB calcium-channel blocker

Ccr creatinine clearance

CHF congestive heart failure

CKD chronic kidney disease

CMS Center for Medicare and Medicaid Services

CONVINCE Controlled Onset Verapamil Investigation of Cardiovascular Endpoints

COX2 cyclo-oxygenase type 2

CTA computerized tomographic angiography

CVD cardiovascular disease

DASH Dietary Approaches to Stop Hypertension

DAVIT Danish Verapamil Infarction Trial

DBP diastolic blood pressure

DEXA dual energy x-ray absorptiometry

DM diabetes mellitus

DOQI Dialysis Outcomes Quality Initiative

ECF extracellular fluid

EEG Electroencephalogram

EPHESUS Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

ESRD end-stage renal disease

FACET Fosinopril Amlodipine Cardiovascular Events Trial

GABA gamma-hydroxybutyric acid

GFR glomerular filtration rate

GITS Gastrointestinal Therapeutic System

GP general population

HARVEST Hypertension and Ambulatory Recording Venetia Study

HCTZ Hydrochlorothiazide

HOPE Heart Outcomes Prevention Evaluation

ICSI Institute for Clinical Systems Improvement

IDNT Irbesartan Diabetic Nephropathy Trial

IHD ischemic heart disease

INSIGHT Intervention as a Goal in Hypertension Treatment

INVEST International Verapamil SR/Trandolapril Study

ISA intrinsic sympathomimetic activity

JNC Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

KDOQI Kidney Disease Outcomes Quality Initiative

LIFE Losartan Intervention for Endpoint Reduction

LVH left ventricular hypertrophy

MAP mean arterial pressure

MDRD Modification of Diet in Renal Disease

MI myocardial infarction

MNT Medical Nutrition Therapy

MRA magnetic resonance angiography

NCHS National Center for Health Statistics

NHANES III Third National Health and Nutrition Examination Survey

NHBPEP National High Blood Pressure Educational Program

NHLBI National Heart, Lung, and Blood Institute

NKF National Kidney Foundation

NORDIL Nordic Diltiazem

NSAID Nonsteroidal anti-inflammatory agent

NYHA New York Heart Association

PGC intra-glomerular pressure

PKD polycystic kidney disease

PRA plasma renin activity

PREVEND Prevention of Renal and Vascular End Stage Disease

PTRA percutaneous transluminal renal angioplasty

PVD peripheral vascular disease

QA single nephron blood flow

RA afferent arteriolar resistance

RAD renal artery disease

RALES Randomized Aldactone Evaluation Study

RAS renin-angiotensin system

RCT randomized controlled trial

RDA recommended daily allowance

RE efferent arteriolar resistance

REIN Ramipril Efficacy in Nephropathy

RENAAL Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan

ROC receiver operator curves

RVHT renovascular hypertension

SBP systolic blood pressure

Scr serum creatinine concentration

SD standard deviation

SGA subjective global assessment

SIGN Scottish Intercollegiate Guidelines Network

SMBP self-measured blood pressure

SNGFR single-nephron GFR

SNP single nucleotide polymorphism

Syst-China Systolic Hypertension in China

Syst-Eur Systolic Hypertension in Europe

TIA transient ischemic attack

UAC urinary albumin concentration

USRDS United States Renal Data System

WCH white-coat hypertension